LCTX
Lineage Cell Therapeutics
$1.03
$0.00 (0%)Jul 27, 2026
Key metrics
The numbers that frame LCTX today
- Market cap
- $256.78M
- P/E (TTM)
- -4.0
- EV / FCF
- -9.9
- Gross margin
- 99.3%
- EV / Sales
- 15.1
- ROIC
- -638.4%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $0.95
- 52wk High
- $2.09
Growth
Revenue and earnings trend for LCTX
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about LCTX
Is Lineage Cell Therapeutics a good buy?
No. Lineage Cell Therapeutics has poor quality and weak momentum. Both signals point to a weaker setup. Growth looks poor. That could put pressure on the long-term business case. We think Lineage Cell Therapeutics is selling at a very high price.
What is the market capitalization of LCTX?
Lineage Cell Therapeutics's market capitalization is $256.78M.
What is the P/E ratio for LCTX stock?
Lineage Cell Therapeutics's current P/E ratio is -4.
What is the 52-week high for LCTX stock?
The 52-week high for Lineage Cell Therapeutics is $2.09. The current close of $1.03 is 50.7% below that high.
What is the 52-week low for LCTX stock?
The 52-week low for Lineage Cell Therapeutics is $0.95. The current close of $1.03 is 8.4% above that low.
Does LCTX stock pay dividends?
Lineage Cell Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for LCTX?
Lineage Cell Therapeutics's Debt / Equity ratio is 0.04.